Inclisiran ameliorates diabetes-associated skeletal muscle remodeling through modulation of FOXO1/PDK4 and ER stress-UPR signaling
Type 2 diabetes mellitus (T2DM) is accompanied by pathological alterations in skeletal muscle, yet effective therapeutic strategies targeting these alterations remain limited. Current interventions, including exercise and nutritional supplementation, often exhibit poor long-term adherence and limited efficacy under...